Patents
Cancer therapies are undergoing a seismic shift with patents emerging that unlock new molecular vulnerabilities. Among the most promising are compounds designed to disable WRN helicase, a DNA repair enzyme uniquely essential to cancers exhibiting microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR). These inventions strike at the heart of tumor survival while sparing healthy cells, offering hope in settings where immunotherapies or chemotherapy resistance prevail. Alongside these inhibitors, novel antibody approaches—such as those targeting mutant calreticulin—extend the toolkit of selective, mechanism-driven cancer therapeutics. Collectively, these patents mark a decisive step toward precision oncology.
Top Posts
- Bicyclic WRN Inhibitors
- Introduces compounds disrupting WRN helicase in MSI-H/dMMR cancers.
- Selectivity spares healthy cells dependent on intact DNA repair.
- Mechanism distinct from immunotherapy, preserving efficacy in resistant tumors.
- Tricyclic WRN Inhibitors
- Structural class binding WRN, obstructing both helicase and ATPase activity.
- Potent in models resistant to standard treatments.
- Allows potential use alone or in therapy combinations.
- Anti-Mutant CALR Antibodies
- Targets malignant CALR mutations in myeloproliferative neoplasms.
- Enables selective immunotherapy without affecting normal CALR.
- Bispecific formats recruit T cells directly to cancerous cells.
Bicyclic compounds as inhibitors of wrn
Bicyclic compounds as inhibitors of wrn New compounds are designed
Tricyclic compounds as inhibitors of wrn
Tricyclic compounds as inhibitors of wrn Compounds selectively target WRN
Anti-mutant calreticulin (calr) antibodies and uses thereof
Anti-mutant calreticulin (calr) antibodies and uses thereof The patent discloses